N-cyano-N'-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]-N"-methylguanidine | 66357-17-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-cyano-N'-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]-N"-methylguanidine
• 英文别名: N-cyano-N'-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]-N''-methylguanidine；N-(2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-N''-cyanoguanidine；1-cyano-3-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-2-methylguanidine
• CAS: 66357-17-3
• 化学式: C₁₃H₂₁N₅OS
• 分子量: 295.409
• InChiKey: PRNVIKLDENQXRZ-UHFFFAOYSA-N

物化性质

• 沸点：
  390.9±52.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  20
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  癸二酸 以 乙醇 为溶剂， 生成 N-cyano-N'-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]-N"-methylguanidine
  参考文献：
  名称：

  Aminoalkyl furan derivatives

  摘要：

  通式I的化合物：##STR1##及其生理上可接受的盐和N-氧化物和水合物，其中R.sub.1和R.sub.2可以相同也可以不同，代表氢、较低的烷基、环烷基、较低的烯基、芳基烷基或被氧原子或基团##STR2##中断的较低烷基，其中R.sub.4代表氢或较低烷基或R.sub.1和R.sub.2可以与它们连接的氮原子一起形成可能包含其他杂原子O和##STR3##的杂环环，R.sub.3是氢、较低烷基、较低烯基或烷氧基烷基；X是--CH.sub.2--、O或S；Y代表.dbd. S、.dbd. O、.dbd. NR.sub.5或.dbd. CHR.sub.6；Alk表示由1到6个碳原子的直链或支链烷基链；R.sub.5是H、硝基、氰基、较低烷基、芳基、烷基磺酰基或芳基磺酰基；R.sub.6代表硝基、芳基磺酰基或烷基磺酰基；M是从2到4的整数；N是1或2；或当X.dbd.S或--CH.sub.2--时，n为零、1或2。这些化合物具有H.sub.2-拮抗活性。还提供了其生产中间体。

  公开号：

  US04128658A1

文献信息

• N'-Derivatives of N-(2-mercapto-ethyl)-2-nitro-1,1-ethenediamine
  申请人：Allen & Hansbury, Limited

  公开号：US04169855A1

  公开（公告）日：1979-10-02

  Compounds of the general formula: ##STR1## in which R.sub.3 is hydrogen, lower alkyl, lower alkenyl or alkoxyalkyl. These compounds are useful in the preparation of novel aminoalkyl furan derivatives having a selective action on histamine receptors.

  一般式为##STR1##的化合物，其中R.sub.3为氢、低级烷基、低级烯基或烷氧基烷基。这些化合物在制备具有对组胺受体选择性作用的新型氨基烷基呋喃衍生物中非常有用。
• Furan derivatives having selective action on histamine receptors
  申请人：Allen & Hanburys Limited

  公开号：US04255440A1

  公开（公告）日：1981-03-10

  Compounds of the general formula I: ##STR1## and physiologically acceptable salts thereof and N-oxides and hydrates, in which R.sub.1 and R.sub.2 which may be the same or different represent hydrogen, lower alkyl, cycloalkyl, lower alkenyl, aralkyl or lower alkyl interrupted by an oxygen atom or a group ##STR2## in which R.sub.4 represents hydrogen or lower alkyl or R.sub.1 and R.sub.2 may, together with the nitrogen atom to which they are attached, form a heterocyclic ring which may contain other heteroatoms selected from O and ##STR3## R.sub.3 is hydrogen, lower alkyl, lower alkenyl or alkoxyalkyl; X is --CH.sub.2 --, O-- or --S--; Y represents .dbd.S, .dbd.O, .dbd.NR.sub.5 or .dbd.CHR.sub.6 ; Alk denotes a straight or branched alkylene chain of 1 to 6 carbon atoms; R.sub.5 is H, nitro, cyano, lower alkyl, aryl, alkylsulphonyl, or arylsulphonyl; R.sub.6 represents nitro, arylsulphonyl or alkylsulphonyl; m is an integer from 2 to 4; and n is 1 or 2; or when X is --S-- or --CH.sub.2 --, n is zero, 1 or 2. These compounds have H.sub.2 -antagonist activity. Intermediates in the production thereof are also provided.

  一般式为I的化合物：## STR1 ##及其生理上可接受的盐和N-氧化物和水合物，其中R.sub.1和R.sub.2可能相同或不同，代表氢，低烷基，环烷基，低烯基，芳基烷基或被氧原子或群体## STR2 ##中断的低烷基，其中R.sub.4代表氢或低烷基，或R.sub.1和R.sub.2可以与它们附着的氮原子一起形成可能包含其他杂原子（如O和## STR3 ##）的杂环，R.sub.3为氢，低烷基，低烯基或烷氧基烷基；X为--CH.sub.2 --，O--或--S--；Y代表.dbd.S，.dbd.O，.dbd.NR.sub.5或.dbd.CHR.sub.6；Alk表示1到6个碳原子的直链或支链烷基链；R.sub.5为H，硝基，氰基，低烷基，芳基烷基，烷基磺酰基或芳基磺酰基；R.sub.6代表硝基，芳基磺酰基或烷基磺酰基；m为2至4的整数；n为1或2；或当X为--S--或--CH.sub.2 --时，n为零，1或2。这些化合物具有H.sub.2-拮抗剂活性。还提供了其生产的中间体。
• Medicated chewing-gum
  申请人：——

  公开号：US20030118691A1

  公开（公告）日：2003-06-26

  The present invention is directed to chewing-gum preparations which are particularly useful for treating gastroesophageal reflux disease. Typically, the chewing-gum preparation comprises a chewing-gum base and more than one ingredient selected from the group consisting of an acid neutralizing agent, an anti-gas agent, and an acid production inhibitor, and desirably all three ingredients. The invention is also directed to a method for treating gastroesophageal reflux disease comprising the step of masticating a chewing-gum preparation including a gum base and more than one ingredient selected from the group consisting of an acid neutralizing agent, an anti-gas agent, and an acid production inhibitor, and desirably all three ingredients.

  本发明涉及特别适用于治疗胃食管反流病的口香糖制剂。通常，口香糖制剂包括口香糖基质和一种以上的成分，这些成分选自酸中和剂、抗气剂和产酸抑制剂组成的组，最好三种成分都有。本发明还涉及一种治疗胃食管反流病的方法，该方法包括咀嚼口香糖制剂的步骤，口香糖制剂包括口香糖基质和一种以上选自酸中和剂、抗气剂和产酸抑制剂组的成分，最好是所有三种成分。
• Histamine and CCK2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer
  申请人：Wang C. Timothy

  公开号：US20050042283A1

  公开（公告）日：2005-02-24

  The present invention relates to methods useful for treating or preventing gastrointestinal disorders. More specifically, the invention relates to methods for the treatment and prevention of acid reflux disease (GERD), peptic ulcer disease, dyspepsia, gastritis, and pre-malignant and malignant disease of the stomach.

  本发明涉及治疗或预防胃肠道疾病的方法。更具体地说，本发明涉及治疗和预防胃酸反流病（GERD）、消化性溃疡病、消化不良、胃炎以及胃的恶性和恶性前期疾病的方法。
• Promoting whole body health
  申请人：Doyle Joseph Matthew

  公开号：US20060193790A1

  公开（公告）日：2006-08-31

  The present invention relates to promoting whole body health in humans and animals by using topical oral compositions comprising a safe and effective amount of a host-response modulating agent in admixture with a pharmaceutically acceptable carrier, said compositions being effective in mediating host reaction to the presence of periodontal pathogens in the oral cavity as well as the toxins and endotoxins released by these pathogens and the inflammatory cytokines and mediators prompted by these oral pathogens.

  本发明涉及通过使用局部口服组合物促进人类和动物的全身健康，所述组合物包含安全有效量的宿主反应调节剂，并与药学上可接受的载体混合，所述组合物能有效调节宿主对口腔中存在的牙周病原体以及这些病原体释放的毒素和内毒素以及这些口腔病原体引发的炎症细胞因子和介质的反应。